Hoyt Casey 4

What Happened

• Hoyt Casey, CEO of Viemed Healthcare (VMD), completed derivative exercises/conversions on Jan 17, 2026 and had shares withheld/settled to cover tax and cash obligations (~$162,250). On Jan 19, 2026 he was granted long-term awards: 172,155 restricted stock units (RSUs) and 43,039 phantom share units (215,194 total). The RSUs and phantom awards vest in three equal annual installments beginning on the first anniversary of the grant.

Key Details

• 2026-01-17: Exercise/conversion of derivatives (code M) resulting in reported acquisitions/conversions of 40,068 and 10,017 underlying shares (some reported as acquired, some as disposed in related entries).
• 2026-01-17: Tax withholding (code F) — 12,118 shares were withheld/surrendered at $7.33 per share = $88,825 (per-share value based on 2026-01-16 close).
• 2026-01-17: Disposition to issuer (code D) — 10,017 shares disposed to the issuer at $7.33 = $73,425.
• 2026-01-17: Additional derivative entries reported as dispositions (M) — 40,068 shares at $0.00 and 10,017 shares (N/A price) related to cash settlement of phantom shares; these are reported as derivative settlements.
• 2026-01-19: Grant/award (code A) — 172,155 RSUs granted (vest in 3 equal annual installments; each RSU = right to one common share).
• 2026-01-19: Grant/award (code A) — 43,039 phantom share units granted (cash-settled equivalents; vest in 3 equal annual installments).
• Shares owned after the transactions: not disclosed in the provided Form 4.
• Footnotes: RSUs convert 1:1 to common shares when vested; phantom shares are cash-settled based on share price at vesting; the filing shows share withholding/sales to cover tax liabilities.

Context

• These entries reflect routine insider activity around option/derivative conversion and tax withholding: derivatives were exercised/converted, and some underlying shares were withheld or sold back to the company to satisfy tax/cash obligations (often called a cashless or net settlement). The new RSU and phantom awards are time‑based compensation that vest over three years and do not represent an immediate open‑market purchase or sale.